Revenue (Tables)

12 Months Ended

Dec. 31, 2021

Revenue

Schedule of reportable segment included under sales category

	2021						2020						2019
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	3,539	$	3,539	$	—	$	3,209	$	3,209	$	—	$	3,392	$	3,392
Other		—		1,179		1,179		—		1,094		1,094		—		1,094		1,094
Total		—		4,718		4,718		—		4,303		4,303		—		4,486		4,486
Nutritionals —
Pediatric Nutritionals		2,192		2,106		4,298		1,987		2,140		4,127		1,879		2,282		4,161
Adult Nutritionals		1,364		2,632		3,996		1,292		2,228		3,520		1,231		2,017		3,248
Total		3,556		4,738		8,294		3,279		4,368		7,647		3,110		4,299		7,409
Diagnostics —
Core Laboratory		1,145		3,983		5,128		1,166		3,309		4,475		1,086		3,570		4,656
Molecular		566		861		1,427		621		817		1,438		149		293		442
Point of Care		384		152		536		369		147		516		438		123		561
Rapid Diagnostics		5,034		3,519		8,553		2,618		1,758		4,376		1,214		840		2,054
Total		7,129		8,515		15,644		4,774		6,031		10,805		2,887		4,826		7,713
Medical Devices —
Rhythm Management		1,018		1,180		2,198		903		1,011		1,914		1,057		1,087		2,144
Electrophysiology		778		1,129		1,907		660		918		1,578		742		979		1,721
Heart Failure		654		235		889		547		193		740		574		195		769
Vascular		915		1,739		2,654		853		1,486		2,339		1,047		1,803		2,850
Structural Heart		730		880		1,610		540		707		1,247		616		784		1,400
Neuromodulation		616		165		781		564		138		702		660		171		831
Diabetes Care		1,212		3,116		4,328		864		2,403		3,267		678		1,846		2,524
Total		5,923		8,444		14,367		4,931		6,856		11,787		5,374		6,865		12,239
Other		34		18		52		38		28		66		27		30		57
Total	$	16,642	$	26,433	$	43,075	$	13,022	$	21,586	$	34,608	$	11,398	$	20,506	$	31,904

Schedule of changes in contract liabilities

(in millions)
Contract Liabilities:
Balance at December 31, 2019	$	294
Unearned revenue from cash received during the period		505
Revenue recognized related to contract liability balance		(394)
Balance at December 31, 2020		405
Unearned revenue from cash received during the period		615
Revenue recognized related to contract liability balance		(500)
Balance at December 31, 2021	$	520